General ~ Therapy / Treatment
~ Genetics of Breast & Ovarian Cancer

When a reference combines three or more of the therapy subcategories, or is beyond the scope of any of them

List was last updated on Dec 1, 2019 @ 7:53 am.


    • The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient's perspective.
    • Sidorenkov G, Nagel J, Meijer C, Duker JJ, Groen HJM, Halmos GB, Oonk MHM, Oostergo RJ, van der Vegt B, Witjes MJH, Nijland M, Havenga K, Maduro JH, Gietema JA, de Bock GH.
    • J Transl Med. 2019 Nov 14;17(1):374. doi: 10.1186/s12967-019-2122-x.
    • Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
    • Wickstroem K, Karlsson J, Ellingsen C, Cruciani V, Kristian A, Hagemann UB, Bjerke RM, Ryan OB, Linden L, Mumberg D, Brands M, Cuthbertson A.
    • Pharmaceuticals (Basel). 2019 Oct 15;12(4). pii: E155. doi: 10.3390/ph12040155.
    • The role of BRCA1/2 in hereditary and familial breast and ovarian cancers.
    • Hawsawi YM, Al-Numair NS, Sobahy TM, Al-Ajmi AM, Al-Harbi RM, Baghdadi MA, Oyouni AA, Alamer OM.
    • Mol Genet Genomic Med. 2019 Jul 17:e879. doi: 10.1002/mgg3.879. [Epub ahead of print]
    • Low Prevalence of the Four Common Colombian Founder Mutations in BRCA1 and BRCA2 in Early-Onset and Familial Afro-Colombian Patients with Breast Cancer.
    • Vargas E, Torres Lopez DM, de Deugd R, Gil F, Nova A, Mora L, Viaña LF, Hernandez JD, Bruges R, Hamann U.
    • Oncologist. 2019 Jul;24(7):e475-e479. doi: 10.1634/theoncologist.2018-0346. Epub 2018 Dec 12.
    • AstraZeneca, Merck's Lynparza, Myriad Genetics' BRCA Test Approved in Japan.
    • [No author given]
    • GenomeWeb. 2019 Jun 19.
    • European Commission Approves Lynparza for Advanced Ovarian Cancer With BRCA Mutations.
    • [No author given]
    • Precision Oncology News (GenomeWeb). 2019 Jun 18.
    • Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers.
    • George A.
    • Curr Genet Med Rep. 2019 May 9. doi: 10.1007/s40142-019-00167-6. [Epub ahead of print]
    • Review
    • Clinical findings and outcomes of MRI staging of breast cancer in a diverse population.
    • Raghavendra A, Wecsler J, Ji L, Sheth P, Ricker C, Church T, Sposto R, Lang J, Sener S, Larsen L, Tripathy D.
    • Breast Cancer Res Treat. 2019 Apr;174(2):315-324. doi: 10.1007/s10549-018-05084-w. Epub 2018 Dec 12.
    • Review
    • Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.
    • Madariaga A, Lheureux S, Oza AM.
    • Cancers (Basel). 2019 Mar 23;11(3). pii: E416. doi: 10.3390/cancers11030416.
    • The cost of cancer care and impact of financial hardship on treatment.
    • [No author given]
    • FORCE. XRAYS. 2019 Feb 8.

    Original research:

    BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.

    News: Labs, Advocacy Groups Push Back on Medicare Policy Shift on NGS Testing for Hereditary Cancer Risk. (GenomeWeb)

    News: Pricey Precision Medicine Often Financially Toxic For Cancer Patients. (Kaiser Health News)

    • Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    • Wu L, Zhong L.
    • J Med Econ. 2019 Feb;22(2):187-195. doi: 10.1080/13696998.2018.1557199. Epub 2019 Jan 4.
    • Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients.
    • Lambertini M, Di Maio M, Poggio F, Pagani O, Curigliano G, Mastro LD, Paluch-Shimon S, Loibl S, Partridge AH, Azim HA Jr, Peccatori FA, Demeestere I.
    • Reprod Biomed Online. 2019 Jan 10. pii: S1472-6483(19)30011-2. doi: 10.1016/j.rbmo.2018.11.031. [Epub ahead of print]
    • Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report.
    • Wolfe AR, Jain R, Pawlik TM, Walker J, Williams TM.
    • Adv Radiat Oncol. 2018 Sep 7;4(1):10-14. doi: 10.1016/j.adro.2018.08.025. eCollection 2019 Jan-Mar.
    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • The Challenge of Evaluating Adnexal Masses in Patients With Breast Cancer.
    • Reinert T, Nogueira-Rodrigues A, Kestelman FP, Ashton-Prolla P, Graudenz MS, Bines J.
    • Clin Breast Cancer. 2018 Aug;18(4):e587-e594. doi: 10.1016/j.clbc.2018.03.006. Epub 2018 Mar 12.
    • Review
    • Combined Treatment Modalities for High-Energy Proton Irradiation: Exploiting Specific DNA Repair Dependencies.
    • Deycmar S, Pruschy M.
    • Int J Part Ther. 2018 Summer;5(1):133-139. doi: 10.14338/IJPT-18-00020.1. Epub 2018 Sep 21.
    • Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.
    • Gast KC, Viscuse PV, Nowsheen S, Haddad TC, Mutter RW, Wahner Hendrickson AE, Couch FJ, Ruddy KJ.
    • Curr Treat Options Cardiovasc Med. 2018 Mar 1;20(2):18. doi: 10.1007/s11936-018-0609-z.
    • Review
    • BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far.
    • Sharma B, Preet Kaur R, Raut S, Munshi A.
    • Curr Probl Cancer. 2018 Mar - Apr;42(2):189-207. doi: 10.1016/j.currproblcancer.2018.01.001. Epub 2018 Jan 8.
    • Review
    • A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors.
    • Shailani A, Kaur RP, Munshi A.
    • Med Oncol. 2018 Jan 31;35(3):18. doi: 10.1007/s12032-018-1085-8.
    • Review
    • Considerations in Testing for Inherited Breast Cancer Predisposition in the Era of Personalized Medicine.
    • Powers B, Pal T, Laronga C.
    • Surg Oncol Clin N Am. 2018 Jan;27(1):1-22. doi: 10.1016/j.soc.2017.08.003.
    • Review
    • SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine.
    • Warner JL, Prasad I, Bennett M, Arniella M, Beeghly-Fadiel A, Mandl KD, Alterovitz G.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00292. Epub 2018 May 1.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Clinical Management of Carriers of BRCA Pathogenic Variants. Treatment Strategies. Breast cancer.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Clinical Management of Carriers of BRCA Pathogenic Variants. Treatment Strategies. Ovarian cancer.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • Final report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology, on a fact-finding questionnaire on the status of treatment of hereditary breast and ovarian cancer syndrome in Japan.
    • Satoh T, Takamatsu K, Takeshima N, Kobayashi H, Aoki D, Suzuki N.
    • J Obstet Gynaecol Res. 2017 Sep;43(9):1377-1380. doi: 10.1111/jog.13409. Epub 2017 Aug 17.
    • The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination.
    • van den Tempel N, Laffeber C, Odijk H, van Cappellen WA, van Rhoon GC, Franckena M, Kanaar R.
    • Oncotarget. 2017 Jul 4;8(27):44593-44604. doi: 10.18632/oncotarget.17861.
    • Development of PARP inhibitors in gynecological malignancies.
    • Ang YLE, Tan DSP.
    • Curr Probl Cancer. 2017 Jul - Aug;41(4):273-286. doi: 10.1016/j.currproblcancer.2017.02.008. Epub 2017 Mar 14.
    • Review
    • BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
    • Rosenberg SM, Ruddy KJ, Tamimi RM, Gelber S, Schapira L, Come S, Borges VF, Larsen B, Garber JE, Partridge AH.
    • JAMA Oncol. 2016 Jun 1;2(6):730-6. doi: 10.1001/jamaoncol.2015.5941.

    Editorial

    Increased Reach of Genetic Cancer Risk Assessment as a Tool for Precision Management of Hereditary Breast Cancer.

    Press: BRCA Mutation Testing Increasing in Younger Women (Medscape Oncology)

    Press: More than 'Angelina Jolie Effect': BRCA tests spike among breast cancer patients. (Fred Hutch News Service)

    Press: More Young Women With Breast Cancer Are Undergoing Genetic Testing, Study Finds. (GenomeWeb)

    • Evolving Approaches in Research and Care for Ovarian Cancers: A Report From the National Academies of Sciences, Engineering, and Medicine.
    • Levine DA, Karlan BY, Strauss JF 3rd.
    • JAMA. 2016 May 10;315(18):1943-4. doi: 10.1001/jama.2016.2640.
    • BRCAness revisited.
    • Lord CJ, Ashworth A.
    • Nat Rev Cancer. 2016 Feb;16(2):110-20. doi: 10.1038/nrc.2015.21. Epub 2016 Jan 18.
    • Review, Editorial / Commentary
    • YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.
    • Stachelek GC, Peterson-Roth E, Liu Y, Fernandez RJ 3rd, Pike LR, Qian JM, Abriola L, Hoyer D, Hungerford W, Merkel J, Glazer PM.
    • Mol Cancer Res. 2015 Oct;13(10):1389-97. doi: 10.1158/1541-7786.MCR-15-0036. Epub 2015 Jun 26.
    • Alison's Story-A Cautionary Tale in the Age of Genomic Medicine.
    • Burn J.
    • Surg Oncol Clin N Am. 2015 Oct;24(4):635-637. doi: 10.1016/j.soc.2015.06.010. Epub 2015 Aug 14.
    • Review
    • Treatment Decision Making and Genetic Testing for Breast Cancer: Mainstreaming Mutations.
    • Katz SJ, Kurian AW, Morrow M.
    • JAMA. 2015 Sep 8;314(10):997-998. doi: 10.1001/jama.2015.8088.
    • Editorial / Commentary
    • CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015-Still in the Ballpark.
    • Narod SA, Dent RA, Foulkes WD.
    • Clin Cancer Res. 2015 Sep 1;21(17):3813-4. doi: 10.1158/1078-0432.CCR-14-3122.

    Triple-negative breast cancer: clinical features and patterns of recurrence.

    • To BRCA or Not to PALB.
    • McNamara MG, Lamarca A, Hubner RA, Valle JW.
    • J Clin Oncol. 2015 Aug 10;33(23):2581-2. doi: 10.1200/JCO.2014.60.0585. Epub 2015 Jun 29.

    Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    • Attitudes toward molecular testing for personalized cancer therapy.
    • Yusuf RA, Rogith D, Hovick SR, Peterson SK, Burton-Chase AM, Fellman BM, Li Y, McKinney C, Bernstam EV, Meric-Bernstam F.
    • Cancer. 2015 Jan 15;121(2):243-250. doi: 10.1002/cncr.28966. Epub 2014 Sep 10.
    • Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis.
    • Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT.
    • Clin Cancer Res. 2015 Jan 1;21(1):211-20. doi: 10.1158/1078-0432.CCR-14-1816. Epub 2014 Oct 27.

    Comment / Letter

    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Letter.

    Reply / Letter

    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Response.

    • [PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
    • Pernin V, Mégnin-Chanet F, Pennaneach V, Fourquet A, Kirova Y, Hall J.
    • Cancer Radiother. 2014 Dec;18(8):790-8; quiz 799-802. doi: 10.1016/j.canrad.2014.05.012. Epub 2014 Oct 17.
    • Review, [Article in French]
    • [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
    • Gaziev AI.
    • Radiats Biol Radioecol. 2014 May-Jun;54(3):229-40.
    • [Article in Russian]
    • Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2.
    • Venkitaraman AR.
    • Science. 2014 Mar 28;343(6178):1470-5. doi: 10.1126/science.1252230.
    • Editorial / Commentary
    • Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
    • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.
    • PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.
    • [Multiple primary malignancies in BRCA1 mutation carriers--two clinical cases].
    • Badora A, Kaleta B, Nowara E, Sikora-Jopek M, Budryk M, Smok-Ragankiewicz A.
    • Ginekol Pol. 2013 Oct;84(10):892-6.
    • No Easy Choices on Breast Reconstruction.
    • Roni Caryn Rabini.
    • NY Times. Well. 2013 May 20.
    • DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy.
    • Mladenov E, Magin S, Soni A, Iliakis G.
    • Front Oncol. 2013 May 10;3:113. doi: 10.3389/fonc.2013.00113. eCollection 2013.
    • Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.
    • Shunkwiler L, Ferris G, Kunos C.
    • Int J Mol Sci. 2013 Feb 8;14(2):3773-85. doi: 10.3390/ijms14023773.
    • Cancer treatment according to BRCA1 and BRCA2 mutations.
    • Maxwell KN, Domchek SM.
    • Nat Rev Clin Oncol. 2012 Aug 14;9(9):520-8. doi: 10.1038/nrclinonc.2012.123. Epub 2012 Jul 24.
    • Review
    • Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
    • Schulz E, Valentin A, Ulz P, Beham-Schmid C, Lind K, Rupp V, Lackner H, Wölfler A, Zebisch A, Olipitz W, Geigl J, Berghold A, Speicher MR, Sill H.
    • J Med Genet. 2012 Jul;49(7):422-8. doi: 10.1136/jmedgenet-2011-100674. Epub 2012 May 31.
    • Managing the breast in patients who test positive for hereditary breast cancer.
    • Euhus D.
    • Ann Surg Oncol. 2012 Jun;19(6):1738-44. doi: 10.1245/s10434-012-2258-x. Epub 2012 Mar 7.
    • Review
    • A surveillance conundrum: a case of 4 distinct primary malignancies in a BRCA-1 mutation carrier.
    • Ricci S, Shafer A, Nerenstone S, Mandavilli S, Sorosky J.
    • Int J Gynecol Pathol. 2012 Mar;31(2):145-8. doi: 10.1097/PGP.0b013e318227ad58.
    • Case Report